CN105431426A - Metap2抑制剂和治疗肥胖症的方法 - Google Patents

Metap2抑制剂和治疗肥胖症的方法 Download PDF

Info

Publication number
CN105431426A
CN105431426A CN201480032972.7A CN201480032972A CN105431426A CN 105431426 A CN105431426 A CN 105431426A CN 201480032972 A CN201480032972 A CN 201480032972A CN 105431426 A CN105431426 A CN 105431426A
Authority
CN
China
Prior art keywords
glycine
subject
compound
bond
phenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480032972.7A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·S·彼得森
詹姆斯·尚南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SynDevRX Inc
Original Assignee
SynDevRX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SynDevRX Inc filed Critical SynDevRX Inc
Priority to CN202011226084.2A priority Critical patent/CN112494476A/zh
Publication of CN105431426A publication Critical patent/CN105431426A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480032972.7A 2013-04-10 2014-04-09 Metap2抑制剂和治疗肥胖症的方法 Pending CN105431426A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011226084.2A CN112494476A (zh) 2013-04-10 2014-04-09 用于治疗肥胖症的化合物的用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361810468P 2013-04-10 2013-04-10
US61/810,468 2013-04-10
US201461925918P 2014-01-10 2014-01-10
US61/925,918 2014-01-10
PCT/US2014/033476 WO2014169026A1 (en) 2013-04-10 2014-04-09 Metap2 inhibitors and methods of treating obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202011226084.2A Division CN112494476A (zh) 2013-04-10 2014-04-09 用于治疗肥胖症的化合物的用途

Publications (1)

Publication Number Publication Date
CN105431426A true CN105431426A (zh) 2016-03-23

Family

ID=51686946

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480032972.7A Pending CN105431426A (zh) 2013-04-10 2014-04-09 Metap2抑制剂和治疗肥胖症的方法
CN202011226084.2A Pending CN112494476A (zh) 2013-04-10 2014-04-09 用于治疗肥胖症的化合物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202011226084.2A Pending CN112494476A (zh) 2013-04-10 2014-04-09 用于治疗肥胖症的化合物的用途

Country Status (12)

Country Link
US (9) US9173956B2 (https=)
EP (2) EP3574922B1 (https=)
JP (5) JP6420314B2 (https=)
CN (2) CN105431426A (https=)
AU (1) AU2014250983B2 (https=)
BR (1) BR112015025892A2 (https=)
CA (1) CA2908993C (https=)
DK (2) DK3574922T3 (https=)
EA (1) EA033912B1 (https=)
ES (2) ES2749746T3 (https=)
MX (2) MX386958B (https=)
WO (1) WO2014169026A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114656371A (zh) * 2020-09-14 2022-06-24 广州药本君安医药科技股份有限公司 1,4-环己二胺桥连化合物及在制备治疗糖代谢紊乱疾病的药物中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150022A2 (en) * 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
CA2908993C (en) * 2013-04-10 2023-05-23 Syndevrx, Inc. Metap2 inhibitors and methods of treating obesity
CN106432255A (zh) * 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
ES2893749T3 (es) * 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
CA3239447A1 (en) * 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
JP2022512826A (ja) 2018-10-26 2022-02-07 シンデブルックス，インコーポレイティド ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用
IL314677A (en) * 2022-02-16 2024-10-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Metap2 inhibitors and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037957A (en) * 1987-06-18 1991-08-06 Anders Grubb Cysteine proteinase inhibitor
CN1115564A (zh) * 1993-10-08 1996-01-24 药制品公司 聚合物键接的喜树碱衍生物
WO2004110358A2 (en) * 2003-05-15 2004-12-23 Vectramed, Inc. Polymeric conjugates for tissue activated drug delivery
US20060206948A1 (en) * 2005-03-09 2006-09-14 Zhao Allan Z Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2009051706A2 (en) * 2007-10-17 2009-04-23 Merck & Co., Inc. Peptide compounds for treating obesity and insulin resistance
US20110294952A1 (en) * 2010-05-25 2011-12-01 SynDevRX Optimized Drug Conjugates

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US20030220233A1 (en) * 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1999011272A1 (en) 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US6306819B1 (en) 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
EA003398B1 (ru) 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
CN1191093C (zh) 1998-10-30 2005-03-02 第一制药株式会社 Dds化合物及其测定方法
AU7025600A (en) 1999-09-08 2001-04-10 School Of Pharmacy, University Of London, The Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US20070161570A1 (en) * 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
DE60233420D1 (de) 2001-09-27 2009-10-01 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
EP1483579A4 (en) 2002-02-15 2006-07-12 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF
EP1494662B1 (en) 2002-04-11 2012-11-28 Children's Medical Center Corporation Tnp-470-hpma-methacrylic acid copolymer conjugates and use thereof
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
CN102989009B (zh) 2003-12-31 2015-06-03 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
JP2008528574A (ja) * 2005-01-26 2008-07-31 チョン クン ダン ファーマシューティカル コープ． フマギロール誘導体またはフマギロール誘導体の製造方法およびこれを含む医薬用組成物
US20080248030A1 (en) 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
JP2010531896A (ja) 2007-06-26 2010-09-30 チルドレンズ メディカル センター コーポレーション 治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US8586019B2 (en) 2008-05-22 2013-11-19 Ramot At Tel-Aviv University Ltd. Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) * 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
TWI373345B (en) * 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
US20130266578A1 (en) * 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
AU2011336785A1 (en) * 2010-11-29 2013-06-20 Zafgen, Inc Treatment of obesity using non-daily administration of 6-0-(4 - dimethylaminoethoxy) cinnamoyl fumagillol
KR101875988B1 (ko) * 2011-03-08 2018-07-06 자프겐 인크. 옥사스피로[2.5]옥탄 유도체 및 유사체
CA2908993C (en) 2013-04-10 2023-05-23 Syndevrx, Inc. Metap2 inhibitors and methods of treating obesity
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
ES2893749T3 (es) 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
CA3239447A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037957A (en) * 1987-06-18 1991-08-06 Anders Grubb Cysteine proteinase inhibitor
CN1115564A (zh) * 1993-10-08 1996-01-24 药制品公司 聚合物键接的喜树碱衍生物
WO2004110358A2 (en) * 2003-05-15 2004-12-23 Vectramed, Inc. Polymeric conjugates for tissue activated drug delivery
US20060206948A1 (en) * 2005-03-09 2006-09-14 Zhao Allan Z Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2009051706A2 (en) * 2007-10-17 2009-04-23 Merck & Co., Inc. Peptide compounds for treating obesity and insulin resistance
US20110294952A1 (en) * 2010-05-25 2011-12-01 SynDevRX Optimized Drug Conjugates

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114656371A (zh) * 2020-09-14 2022-06-24 广州药本君安医药科技股份有限公司 1,4-环己二胺桥连化合物及在制备治疗糖代谢紊乱疾病的药物中的应用
CN114656371B (zh) * 2020-09-14 2024-03-12 广州药本君安医药科技股份有限公司 1,4-环己二胺桥连化合物及在制备治疗糖代谢紊乱疾病的药物中的应用

Also Published As

Publication number Publication date
JP2021091738A (ja) 2021-06-17
CN112494476A (zh) 2021-03-16
EP2984085A4 (en) 2016-12-07
JP2019023219A (ja) 2019-02-14
MX2015014329A (es) 2016-06-21
CA2908993C (en) 2023-05-23
BR112015025892A2 (pt) 2017-07-25
JP6420314B2 (ja) 2018-11-07
US9433600B2 (en) 2016-09-06
CA2908993A1 (en) 2014-10-16
AU2014250983A1 (en) 2015-10-29
ES2749746T3 (es) 2020-03-23
EP2984085A1 (en) 2016-02-17
JP7681054B2 (ja) 2025-05-21
EP3574922B1 (en) 2021-09-15
EA201591943A1 (ru) 2016-07-29
JP2023082195A (ja) 2023-06-13
US20170028014A1 (en) 2017-02-02
DK3574922T3 (da) 2021-12-06
DK2984085T3 (da) 2019-10-21
JP2016519106A (ja) 2016-06-30
ES2902082T3 (es) 2022-03-24
US20160346244A1 (en) 2016-12-01
MX386958B (es) 2025-03-19
US9750737B2 (en) 2017-09-05
US20180271856A1 (en) 2018-09-27
MX371095B (es) 2020-01-16
WO2014169026A1 (en) 2014-10-16
US9173956B2 (en) 2015-11-03
EA033912B1 (ru) 2019-12-09
US10010544B2 (en) 2018-07-03
EP3574922A1 (en) 2019-12-04
US11304944B2 (en) 2022-04-19
US20230048989A1 (en) 2023-02-16
AU2014250983B2 (en) 2019-04-11
HK1216313A1 (en) 2016-11-04
US20260076960A1 (en) 2026-03-19
EP2984085B1 (en) 2019-07-17
US9757373B2 (en) 2017-09-12
US20200155545A1 (en) 2020-05-21
JP2025109807A (ja) 2025-07-25
US20150374657A1 (en) 2015-12-31
US10588904B2 (en) 2020-03-17
US20170326135A1 (en) 2017-11-16
US20140308235A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
JP7681054B2 (ja) Ｍｅｔａｐ２阻害剤及び肥満症の治療方法
CN103140512B (zh) 聚合物缀合的MetAP2抑制剂及其应用的治疗方法
KR20070053214A (ko) 신규 생분해성 링커를 함유하는 프로드럭
HK40018613B (en) Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity
HK40018613A (en) Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity
HK1216313B (en) Modified or polymer-conjugated fumagillol metap2 inhibitors for use in treating obesity
CN1476325B (zh) 活性物质的输送系统和活性物质的保护和施用方法
EA045828B1 (ru) Ингибиторы metap2 и способы восстановления чувствительности к инсулину

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160323

RJ01 Rejection of invention patent application after publication